AXNX News and Press, Axonics Modulation Technologies Inc. From 10/30/23

2023-10-30 16:29:36 ET More on Axonics Modulation Technologies Axonics: Growing Duopolist With Superior Product And No Debt Axonics gets new finance chief Seeking Alpha’s Quant Rating on Axonics Modulation Technologies Historical earnings data for Axon...

Generated quarterly revenue of $93.1 million, an increase of 32% year over year Fiscal year 2023 revenue guidance increased to $362 million Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment o...

FMC Corporation (FMC) is expected to report $0.45 for Q3 2023 NCS Multistage Holdings Inc. (NCSM) is expected to report $2.59 for Q3 2023 Third Century Bancorp (TDCB) is expected to report for Q3 2023 ZoomInfo Technologies Inc. (ZI) is expected to report $0.15 for Q3 2023 Matson I...

Axonics Inc. (AXNX) is expected to report $-0.05 for Q3 2023

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to report third quarter 2023 financial results after the close of trading on Monday, October 30. Axonics wil...

2023-09-07 08:27:07 ET Summary Positioned as one of two companies in an underserved healthcare segment with recession-resistant demand for its services and a better product than the legacy monopolist. Strong historical revenue growth while still in the early stages of company matu...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the following investor conferences in September: Event: Wells Fargo Healthcare Conference ...

2023-08-21 06:55:53 ET More on Axonics Axonics, Shockwave Medical move in response to Medicare proposals Axonics: Rapid Growth But Waiting For Profitability Axonics initiated at overweight at KeyBanc on underserved market Seeking Alpha’s ...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that Dan L. Dearen, president and chief financial officer, is retiring from the company. Kari Keese, vice pre...

2023-08-14 15:22:00 ET Summary Two new Breakout Stocks for Week 33 curated by the MDA model for 10% short-term upside along with one Dow pick. Last week two of four picks gained over the 10% mark in less than a week with peak gains in EHTH +12.3% and ATEX +15.4% still near highs. ...